TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27606561

Group type: EXPERIMENTAL
Intervention: Approximating graft edges (AP)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Overlapping graft edges (OV)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Total Vancouver Scar Score (VSS)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Individual domain VSS scores (height, pliability, vascularity, pigmentation)
Number of subjects: 19
Study: 23897905

Group type: EXPERIMENTAL
Intervention: Turning-based treadmill training for 30 minutes, 12 sessions over 4 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Regular treadmill training for 30 minutes followed by a 10-minute general exercise program, 12 sessions over 4 weeks
Number of subjects: 30
Study: 22389937

Group type: EXPERIMENTAL
Intervention: CIMT 3 hr/day for 21 days
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: CIMT 6 hr/day for 21 days
Number of subjects: 18
Study: 21094358

Group type: EXPERIMENTAL
Intervention: Normal electrocardiograms (ECG)
Number of subjects: 10101

Group type: EXPERIMENTAL
Intervention: Definite ECG Q-wave myocardial infarction (MI)
Number of subjects: 10101

Group type: EXPERIMENTAL
Intervention: ECG evidence of left ventricular hypertrophy
Number of subjects: 10101

Group type: EXPERIMENTAL
Intervention: Abnormal electrocardiograms
Number of subjects: 10101

Group type: EXPERIMENTAL
Intervention: Age-related abnormal electrocardiograms
Number of subjects: 10101

Group type: EXPERIMENTAL
Intervention: Angina and coronary artery bypass graft surgery
Number of subjects: 10101
Study: 17964008

Group type: EXPERIMENTAL
Intervention: Oral nutritional supplements (ONS) for three months in addition to dietary counselling (DC)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Only dietary counselling (DC)
Number of subjects: 80
Study: 15684311

Group type: EXPERIMENTAL
Intervention: Lapatinib (GW572016) administered orally once daily continuously
Number of subjects: 33
Study: 12862418

Group type: COMPARATOR
Intervention: Low dose recombinant human IL-12 (rhIL-12) at doses of 10, 30, and 100 ng/kg, administered subcutaneously or intravenously
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Melan-A26-35 and influenza matrix58-66 peptides administered intradermally on weeks 1, 2, 3, 4, and 9
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Biopsies of accessible tumors
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Low dose rhIL-12 (10-100 ng/kg)
Number of subjects: 28
Study: 10568486

Group type: EXPERIMENTAL
Intervention: Calcipotriol cream (50 microg/g) applied twice a day with oral etretinate (50 mg/day)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Oral etretinate (50 mg/day) alone
Number of subjects: 86
Study: 8739825

Group type: EXPERIMENTAL
Intervention: Phenobarbital 100 mg orally daily for 8 days
Number of subjects: 15

Group type: COMPARATOR
Intervention: Tirilazad mesylate alone
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Phenobarbital + tirilazad
Number of subjects: 15
Study: 1745508

Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine rinse
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 80
Study: 7033825

Group type: EXPERIMENTAL
Intervention: Lisuride (mean daily intake of 4.5 mg)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Bromocriptine (mean daily intake of 56.5 mg)
Number of subjects: 28
Study: 31317805

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 30256747

Group type: EXPERIMENTAL
Intervention: Cryopreserved placental membrane (CPM) applied weekly
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Cryopreserved placental membrane (CPM)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Standard wound care (SWC)
Number of subjects: 26
Study: 27324887

Group type: EXPERIMENTAL
Intervention: RI‐002 (10% Liquid Intravenous Immunoglobulin containing high titer neutralizing antibody to RSV)
Number of subjects: 59
Study: 25181918

Group type: EXPERIMENTAL
Intervention: Pre-implant LVEF < 22% (T(low)); n = 128
Number of subjects: 366

Group type: EXPERIMENTAL
Intervention: Pre-implant LVEF 22% to 28% (T(middle)); n = 121
Number of subjects: 366

Group type: EXPERIMENTAL
Intervention: Pre-implant LVEF > 28% (T(high)); n = 117
Number of subjects: 366
Study: 22245668

Group type: EXPERIMENTAL
Intervention: AQ-SP
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: AQ-SP-PQ
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: MQ-AS
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: MQ-AS-PQ
Number of subjects: 82
Study: 19155454

Group type: EXPERIMENTAL
Intervention: Ready-to-use therapeutic food (RUTF) - 1 packet per day (92 g, 500 kcal/d) for 3 months in intervention villages.
Number of subjects: 3166

Group type: COMPARATOR
Intervention: Control group (no intervention) in nonintervention villages.
Number of subjects: 3166
Study: 18260975

Group type: EXPERIMENTAL
Intervention: Atenolol (AT)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Acebutolol (AC)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Talinolol (TL)
Number of subjects: 60
Study: 15465841

Group type: EXPERIMENTAL
Intervention: Acute normovolaemic haemodilution (ANH), 3 units planned
Number of subjects: 160

Group type: COMPARATOR
Intervention: No acute normovolaemic haemodilution (no ANH)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Transfusion protocol (historical controls)
Number of subjects: 160
Study: 11294535

Group type: EXPERIMENTAL
Intervention: Endoscopic Nd‐YAG laser fulguration
Number of subjects: 1
Study: 9589818

Group type: EXPERIMENTAL
Intervention: Salmeterol powder 50 micrograms twice daily
Number of subjects: 451

Group type: COMPARATOR
Intervention: Albuterol 180 micrograms four times daily
Number of subjects: 451

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 451
Study: 7978586

Group type: EXPERIMENTAL
Intervention: 10 to 15 micrograms/kg of OTFC
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 15 to 20 micrograms/kg of OTFC
Number of subjects: 30
Study: 2563409

Group type: EXPERIMENTAL
Intervention: L‐alanyl‐L‐glutamine (54 mg peptide‐N/kg per day)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control solution (alanine‐N and glycine‐N)
Number of subjects: 12
Study: 51141

Group type: EXPERIMENTAL
Intervention: Amoxycillin 1 g six-hourly for fourteen days
Number of subjects: 124

Group type: COMPARATOR
Intervention: Chloramphenicol
Number of subjects: 124
Study: 31215756

Group type: EXPERIMENTAL
Intervention: Specialist bridging service
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Dabigatran
Number of subjects: 600
Study: 29208797

Group type: EXPERIMENTAL
Intervention: Sodium fluoride varnish applied three times a week for 1 year
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 200
Study: 26001563

Group type: EXPERIMENTAL
Intervention: Lebrikizumab (37.5, 125, 250 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 22934678

Group type: EXPERIMENTAL
Intervention: Educational intervention (1 day of training including lectures, interactive sessions, multimedia demonstrations, and role play)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Fee-for-service intervention (monetary compensation for counselling)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Educational intervention
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Cessation counselling
Number of subjects: 95
Study: 21618158

Group type: EXPERIMENTAL
Intervention: Air-braked ergometer (AE)
Number of subjects: 41
Study: 18056796

Group type: EXPERIMENTAL
Intervention: Exposure to sexist humor (sexist jokes)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exposure to sexist comedy skits
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neutral comedy skits
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonhumorous sexist statements
Number of subjects: 0
Study: 17126638

Group type: EXPERIMENTAL
Intervention: Cranberry juice (250 mL for 7 days)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo (for 7 days)
Number of subjects: 7
Study: 15574079

Group type: EXPERIMENTAL
Intervention: Albuterol (16 mg.day(‐1))
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11350882

Group type: EXPERIMENTAL
Intervention: ALVAC-CEA B7.1 vaccine alone
Number of subjects: 60

Group type: COMPARATOR
Intervention: ALVAC-CEA B7.1 vaccine with GM-CSF
Number of subjects: 60
Study: 9210003

Group type: EXPERIMENTAL
Intervention: Norfloxacin
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Nitrofurantoin
Number of subjects: 21
Study: 7958571

Group type: EXPERIMENTAL
Intervention: Smoking intervention programme (semistructured, using a flip‐over and a booklet) among pregnant women
Number of subjects: 624

Group type: EXPERIMENTAL
Intervention: Smoking intervention programme (semistructured, using a flip‐over and a booklet) among non-pregnant women
Number of subjects: 624

Group type: COMPARATOR
Intervention: Control group for pregnant women
Number of subjects: 624

Group type: COMPARATOR
Intervention: Control group for non-pregnant women
Number of subjects: 624
Study: 3296236

Group type: EXPERIMENTAL
Intervention: Chemonucleolysis (chymopapain injection)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 156
Study: 29654122

Group type: EXPERIMENTAL
Intervention: Factual messages about chemicals in cigarette smoke and their health harms
Number of subjects: 719

Group type: COMPARATOR
Intervention: Messages about not littering cigarette butts
Number of subjects: 719
Study: 28395758

Group type: EXPERIMENTAL
Intervention: Pretherapeutic DPD deficiency screening (arm A)
Number of subjects: 1142

Group type: COMPARATOR
Intervention: No pretherapy screening (arm B)
Number of subjects: 1142
Study: 26306022

Group type: EXPERIMENTAL
Intervention: Ezetimibe in addition to statins
Number of subjects: 0

Group type: COMPARATOR
Intervention: Statins alone
Number of subjects: 0
Study: 24693625

Group type: EXPERIMENTAL
Intervention: 0.454% stannous fluoride dentifrice (SnF2)
Number of subjects: 150

Group type: COMPARATOR
Intervention: 0.3% triclosan/copolymer dentifrice (positive control)
Number of subjects: 150
Study: 21165806

Group type: EXPERIMENTAL
Intervention: IHG1 (4×2‐min contractions at 30% MVC)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: IHG2 (8×1‐min contractions at 30% MVC)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: IHG3 (16×30‐s contractions at 30% MVC)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Sham (4×2‐min contractions at 3% MVC)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: IHG1
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: IHG2
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: IHG3
Number of subjects: 12
Study: 18488808

Group type: EXPERIMENTAL
Intervention: Tablet formulation of sildenafil 100 mg
Number of subjects: 28
Study: 17008146

Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Disulfiram
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Disulfiram and Naltrexone
Number of subjects: 254

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 254
Study: 12836151

Group type: EXPERIMENTAL
Intervention: Intervention group (patients attending the pain center)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Male participants
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patients younger than 65 years of age
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patients presenting with different types of chronic pain other than back pain
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 10847313

Group type: EXPERIMENTAL
Intervention: Melatonin (2 mg, controlled release)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 8794434

Group type: EXPERIMENTAL
Intervention: Clomiphene citrate (CC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (MPA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Estrogen (previously incubated)
Number of subjects: 0
Study: 1627433

Group type: EXPERIMENTAL
Intervention: Oral LMF (chlorambucil, methotrexate, and fluorouracil) for 6 months followed by BCG skin scarifications monthly for up to 2 years
Number of subjects: 254

Group type: COMPARATOR
Intervention: Observation only
Number of subjects: 254
Study: 6328542

Group type: EXPERIMENTAL
Intervention: Oral ketoconazole (200 mg twice daily for 5 days)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Clotrimazole 100 mg vaginal tablets (one per night for 6 days)
Number of subjects: 63
Study: 31562909

Group type: EXPERIMENTAL
Intervention: Minimum partial length groESL sequence for species delineation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Minimal partial sequences for intra-specific diversity analysis
Number of subjects: 0
Study: 28318835

Group type: COMPARATOR
Intervention: d-serine (60mg/kg/d, 6 weeks)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: d-serine (open-label, 30-120mg/kg/d, n=21)
Number of subjects: 16

Group type: COMPARATOR
Intervention: bitopertin (10mg, n=29)
Number of subjects: 16
Study: 27372555

Group type: EXPERIMENTAL
Intervention: Tourniquet group (group T)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Control group (group C)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 109
Study: 23241791

Group type: EXPERIMENTAL
Intervention: Loupe magnification (×3.5)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control (no loupe magnification)
Number of subjects: 81
Study: 22819520

Group type: EXPERIMENTAL
Intervention: Titration based on NOTT guidelines
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Walking tests
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Constant work-rate tests at 12 ml/min/kg
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Single exercise test at 40 W
Number of subjects: 31
Study: 20465169

Group type: EXPERIMENTAL
Intervention: Coherent oscillation in the orthogonal direction of the main visual motion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Variation in phases or nonuniform amplitude
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Uniform oscillation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Visual pattern perceived as more rigid
Number of subjects: 0
Study: 17961726

Group type: EXPERIMENTAL
Intervention: Autologous stem cell transplantation (autoSCT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Continuation chemotherapy
Number of subjects: 0
Study: 15564273

Group type: EXPERIMENTAL
Intervention: Salt consumption and iodine content assessment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Urinary iodine concentration measurement
Number of subjects: 0
Study: 12147587

Group type: EXPERIMENTAL
Intervention: Grating acuity cards (Teller)
Number of subjects: 656

Group type: COMPARATOR
Intervention: Recognition acuity charts (ETDRS or Lea symbol charts)
Number of subjects: 656
Study: 10427139

Group type: EXPERIMENTAL
Intervention: p53 gene mutations
Number of subjects: 178
Study: 7483560

Group type: EXPERIMENTAL
Intervention: Occupational exposure to lead compounds
Number of subjects: 2723

Group type: COMPARATOR
Intervention: Control group (not exposed to lead compounds)
Number of subjects: 2723
Study: 2137995

Group type: EXPERIMENTAL
Intervention: Clobetasole‐17‐propionate cream (topical corticosteroid) applied for 1 week prior to prick tests
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Loratadine (oral H1-antihistamine)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pseudoephedrine (oral alpha 1-adrenoceptor agonist)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7017685

Group type: EXPERIMENTAL
Intervention: Intensive plasma exchange (IPE) combined with conventional anti-rejection therapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional anti-rejection therapy alone (control group)
Number of subjects: 60
Study: 30712629

Group type: EXPERIMENTAL
Intervention: Bioabsorbable interference screw (BS) group
Number of subjects: 60

Group type: COMPARATOR
Intervention: Cortical button (CB) group
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study: 29856848

Group type: EXPERIMENTAL
Intervention: Intermittent use of NuvaRing® (three rings with a ring-free week in between rings)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Continuous use of NuvaRing® (four rings without ring-free weeks)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Both intermittent and continuous use of NuvaRing®
Number of subjects: 120
Study: 26501737

Group type: EXPERIMENTAL
Intervention: Growth hormone (Genotropin®, Pfizer Inc.) at a dose of 0.035 mg/kg/day by subcutaneous injection for 24 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 0
Study: 25112521

Group type: EXPERIMENTAL
Intervention: Online 10 Hz, repetitive transcranial magnetic stimulation (rTMS) over the right precuneus
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vertex stimulation (control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: rPPC stimulation (positive control)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No-TMS condition
Number of subjects: 0
Study: 21815963

Group type: EXPERIMENTAL
Intervention: K/Mg solution pretreatment (n = 84)
Number of subjects: 170
Study: 19054698

Group type: EXPERIMENTAL
Intervention: Thrombolytic treatment (high-dose and low-dose)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Successful thrombolysis
Number of subjects: 121
Study: 17502505

Group type: EXPERIMENTAL
Intervention: Discontinuation of amblyopia treatment (other than spectacle wear)
Number of subjects: 80
Study: 15178163

Group type: EXPERIMENTAL
Intervention: Humorous film
Number of subjects: 35

Group type: COMPARATOR
Intervention: Nonhumorous film
Number of subjects: 35
Study: 12177657

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) administration, 4 IU subcutaneously every other day for 3 months
Number of subjects: 10
Study: 10211615

Group type: EXPERIMENTAL
Intervention: Fine needle cytology with suction
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fine needle cytology without suction
Number of subjects: 0
Study: 7647026

Group type: EXPERIMENTAL
Intervention: Nicorandil
Number of subjects: 0
Study: 2112271

Group type: EXPERIMENTAL
Intervention: Dipyridamole (150 mg twice daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aspirin (25 mg twice daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aspirin (25 mg twice daily) + Dipyridamole (150 mg twice daily)
Number of subjects: 0
Study: 646077

Group type: EXPERIMENTAL
Intervention: Intravenous ketamine and thiopentone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ketamine alone
Number of subjects: 0
Study: 31468650

Group type: EXPERIMENTAL
Intervention: Lactate infusion
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 16
Study: 26847152

Group type: EXPERIMENTAL
Intervention: Mind Sound Resonance Technique (MSRT)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Supine Rest (SR)
Number of subjects: 42
Study: 26318511

Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg
Number of subjects: 9014

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9014
Study: 23114462

Group type: EXPERIMENTAL
Intervention: Whey protein concentrate (WPC) supplementation (40g/day)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Isocaloric control
Number of subjects: 80
Study: 21091349

Group type: EXPERIMENTAL
Intervention: CHX gel 2%
Number of subjects: 20

Group type: COMPARATOR
Intervention: CHX gel after 3 minutes of 24% EDTA gel root surface etching
Number of subjects: 20
Study: 18986598

Group type: EXPERIMENTAL
Intervention: Plant sterol-enriched margarine
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Plant stanol-enriched margarine
Number of subjects: 47

Group type: COMPARATOR
Intervention: Margarine without added plant sterols or stanols
Number of subjects: 47
Study: 16320175

Group type: EXPERIMENTAL
Intervention: Pulsed low-dosed magnetic field (100 uT, basic frequency 30 Hz with frequency modulation)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Pulsed high-dosed magnetic field (8.4 mT, 10 Hz)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 12
Study: 10556002

Group type: EXPERIMENTAL
Intervention: PAPU (150 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 8758049

Group type: EXPERIMENTAL
Intervention: Thoracic electrical bioimpedance (TEB)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oesophageal Doppler monitoring (ODM)
Number of subjects: 0
Study: 1764957

Group type: EXPERIMENTAL
Intervention: Enteric coated naproxen 500 mg (2 tablets at night)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Normal release naproxen 500 mg (1 tablet twice daily)
Number of subjects: 88
Study: 6637358

Group type: EXPERIMENTAL
Intervention: 10 mg kg‐1 cimetidine orally
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 40 mg kg‐1 cimetidine rectally
Number of subjects: 60

Group type: COMPARATOR
Intervention: No premedication
Number of subjects: 60
Study: 30633223

Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES) therapy for 8 weeks
Number of subjects: 86
Study: 29408521

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (24 IU)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo spray
Number of subjects: 120
Study: 26735531

Group type: EXPERIMENTAL
Intervention: Foot pump (A-V Impulse System)
Number of subjects: 120

Group type: COMPARATOR
Intervention: No foot pump
Number of subjects: 120
Study: 24158736

Group type: EXPERIMENTAL
Intervention: Vitamin D
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study: 21989603

Group type: EXPERIMENTAL
Intervention: Sertindole
Number of subjects: 30

Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 30

Group type: COMPARATOR
Intervention: Quetiapine
Number of subjects: 30
Study: 20630899

Group type: EXPERIMENTAL
Intervention: gemcitabine plus S-1 combination therapy
Number of subjects: 100

Group type: COMPARATOR
Intervention: S-1 monotherapy
Number of subjects: 100
Study: 17205320

Group type: EXPERIMENTAL
Intervention: Active nicotine patch (14 mg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Low abstinence reinforcement condition ($5.00 available)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: High abstinence reinforcement condition ($20.00 available)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control session (monetary consequences every 30 s regardless of smoking)
Number of subjects: 30